Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis

Dick Menzies, Andrea Benedetti, Anita Paydar, Ian Martin, Sarah Royce, Madhukar Pai, Andrew Vernon, Christian Lienhardt, William Burman, Dick Menzies, Andrea Benedetti, Anita Paydar, Ian Martin, Sarah Royce, Madhukar Pai, Andrew Vernon, Christian Lienhardt, William Burman

Abstract

Background: Treatment regimens for active tuberculosis (TB) that are intermittent, or use rifampin during only the initial phase, offer practical advantages, but their efficacy has been questioned. We conducted a systematic review of treatment regimens for active TB, to assess the effect of duration and intermittency of rifampin use on TB treatment outcomes.

Methods and findings: PubMed, Embase, and the Cochrane CENTRAL database for clinical trials were searched for randomized controlled trials, published in English, French, or Spanish, between 1965 and June 2008. Selected studies utilized standardized treatment with rifampin-containing regimens. Studies reported bacteriologically confirmed failure and/or relapse in previously untreated patients with bacteriologically confirmed pulmonary TB. Pooled cumulative incidences of treatment outcomes and association with risk factors were computed with stratified random effects meta-analyses. Meta-regression was performed using a negative binomial regression model. A total of 57 trials with 312 arms and 21,472 participants were included in the analysis. Regimens utilizing rifampin only for the first 1-2 mo had significantly higher rates of failure, relapse, and acquired drug resistance, as compared to regimens that used rifampin for 6 mo. This was particularly evident when there was initial drug resistance to isoniazid, streptomycin, or both. On the other hand, there was little evidence of difference in failure or relapse with daily or intermittent schedules of treatment administration, although there was insufficient published evidence of the efficacy of twice-weekly rifampin administration throughout therapy.

Conclusions: TB treatment outcomes were significantly worse with shorter duration of rifampin, or with initial drug resistance to isoniazid and/or streptomycin. Treatment outcomes were similar with all intermittent schedules evaluated, but there is insufficient evidence to support administration of treatment twice weekly throughout therapy.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Summary of literature search and…
Figure 1. Summary of literature search and study selection.

References

    1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3:S231–S279.
    1. World Health Organization. Treatment of tuberculosis: guidelines for national programmes WHO/CDS/TB/2003.313 (Revised June 2004). WHO. 2004;313:1–108.
    1. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis. 1986;133:423–430.
    1. Caminero JA. Treatment of multidrug resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis. 2006;10:829–837.
    1. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001;344:1294–1303.
    1. World Health Organization. Anti-tuberculosis drug resistance in the world (Report no. 4). 2008. WHO/HTM/TB/2008.
    1. WHO and IUATLD. Anti-tuberculosis drug resistance in the world (Report no. 4) 2008
    1. Han T. Effectiveness of standard short-course chemotherapy for treating tuberculosis and the impact of drug resistance on its outcome. Int J Evid Based Healthc. 2006;4:101–117.
    1. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. 2008. Cochrane Database of Systematic Reviews.
    1. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ. 2008;336:484–487.
    1. Gelband H. Regimens of less than six months for treating tuberculosis (review). 1999. Cochrane Database of Systematic Reviews 1.
    1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3:S231–S279.
    1. American Thoracic Society, Infectious Diseases Society of America, Centres for Disease Control. Treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–662.
    1. Public Health Agency of Canada and Canadian Lung Association/Canadian Thoracic Society. Canadian tuberculosis standards. Toronto: Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control; 2007.
    1. Page KR, Chaisson RE. Tuberculosis - HIV coinfection: epidemiology, clinical aspects, and interventions. In: Raviglione MC, editor. Reichman and Hershfield's tuberculosis a comprehensive, international approach. New York: Informa HealthCare; 2006. pp. 371–416.
    1. Rieder HL. Interventions for tuberculosis control and elimination. Paris: International Union against Tuberculosis and Lung Disease; 2002.
    1. World Health Organization, International Union against Tuberculosis and Lung Disease (IUATLD), Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuber Lung Dis. 2001;5:213–215.
    1. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statist Med. 2007;26:53–77.
    1. Higgin JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23:1663–1682.
    1. Hamza TH, Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol. 2008;61:41–51.
    1. Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002;21:1503–1511.
    1. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18:2693–2708.
    1. Singapore Tuberculosis Service, British Medical Research Council. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Lancet. 1975;306:1105–1109.
    1. East African-British Medical Research Council Study. Controlled clinical trial of short-course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1972;299:1079–1085.
    1. Tuberculosis Research Centre. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tuberc. 1983;64:73–91.
    1. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364:1244–1251.
    1. Singapore Tuberculosis Service-British Medical Research Council. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. the results up to 30 months. Am Rev Respir Dis. 1977;116:807–820.
    1. Hong Kong Chest-British Medical Research Council. Controlled trial of four twice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet. 1981;317:171–174.
    1. Balasubramanian R, Sivasubramanian S, Vijayan VK, Ramachandran R, Jawahar MS, et al. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tuberc. 1990;71:253–258.
    1. East African-British Medical Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. second report. Lancet. 1973;1:1331–1338.
    1. East African-British Medical Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. third report. Lancet. 1974;2:237–240.
    1. East African-British Medical Research Council. Controlled clinical trial of four (6-month) 3 regimens of chemotherapy for pulmonary tuberculosis. second report. Am Rev Respir Dis. 1976;114:471–475.
    1. Third East African-British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report. Am Rev Respir Dis. 1978;118:39–48.
    1. Third East African-British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. second report. Tuberc. 1980;61:59–69.
    1. Hong Kong Chest Service and British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. first report. Am Rev Respir Dis. 1978;118:219–228.
    1. Hong Kong Chest Service and British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tuberc. 1979;60:201–210.
    1. Singapore Tuberculosis Service-British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1979;119:579–585.
    1. Singapore Tuberculosis Service-British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tuberc. 1981;62:95–102.
    1. Singapore Tuberculosis Service-British Medical Research Council. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1986;133:779–783.
    1. Hong Kong Chest Service-British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. second report: the results up to 24 months. Tuberc. 1982;63:89–98.
    1. Hong Kong Chest Service-British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1987;136:1339–1342.
    1. Algerian Working Group-British Medical Research Council. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am Rev Respir Dis. 1984;129:921–928.
    1. East and Central African-British Medical Research Council. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tuberc. 1983;64:153–166.
    1. East and Central African-British Medical Research Council Fifth Collaborative. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tuberc. 1986;67:5–15.
    1. Tanzania-British Medical Research Council. Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1985;131:727–731.
    1. Singapore Tuberculosis Service-British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1985;132:374–378.
    1. Singapore Tuberculosis Service-British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1988;137:1147–1150.
    1. Hong Kong Chest Service-Tuberculosis Research Centre MBMRC. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis. 1991;143:262–267.
    1. Hong Kong Chest Service-British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. results at 30 months. Am Rev Respir Dis. 1991;143:700–706.
    1. Singapore Tuberculosis Service-British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis. 1991;143:707–712.
    1. Kenyan-Zambian-British Medical Research Council. Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1989;140:990–995.
    1. Tuberculosis Research Centre Madras. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Am Rev Respir Dis. 1986;134:27–33.
    1. British Medical Research Council. Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. Tuberc. 1973;54:99–129.
    1. British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis. Lancet. 1975;305:119–124.
    1. British Thoracic and Tuberculosis Association, Angel H. Short-course chemotherapy in pulmonary tuberculosis. a controlled trial by the British Thoracic and Tuberculosis Association. Lancet. 1976;2:1102–1104.
    1. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. first report: results during chemotherapy. Br J Dis Chest. 1981;75:141–153.
    1. Zierski M, Bek E, Long MW, Snider DE,, Jr. Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis. 1981;124:249–251.
    1. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis. 1982;126:460–462.
    1. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. S Afr Med J. 1994;84:325–327.
    1. Felten MK. Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis. S Afr Med J. 1989;75:524–526.
    1. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest. 1992;102:1815–1818.
    1. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P the Rifabutin Study Group. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuberc Lung Dis. 1994;75:341–347.
    1. Algerian Working Group British Medical Research Council Cooperative Study. Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Tuberc. 1991;72:88–100.
    1. Tripathy SP. Controlled clinical trial of a 3-month and two 5-month regimens in pulmonary tuberculosis. Second Madras short course study. Bull Int Union Tuberc. 1983;58:97–100.
    1. Su W-J, Perng R-P. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis. 2002;6:1029–1032.
    1. Zhang LX, Kan GQ, Tu DH, Wan LY, Faruqi AR. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Curr Ther Res. 1996;57:849–856.
    1. Corpe R. Rifampin in original treatment of pulmonary tuberculosis: a United States public health service cooperative therapy trial. Bull Int Union Tuberc. 1972;47:41–47.
    1. Howell F, O'Laoide R, Kelly P, Power J, Clancy L. Short course chemotherapy for pulmonary tuberculosis: a randomised controlled trial of a six month versus a nine month oral regimen. Ir Med J. 1989;82:11–13.
    1. Snider DE, Gracyk J, Bek E, Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis. 1984;130:1091–1094.
    1. Santha T, Nazareth O, Krishnamurthy MS, Balasubramanian R, Vijayan VK, et al. Treatment of pulmonary tuberculosis with short course chemotherapy in south India-5 year follow up. Tuberc. 1989;70:229–234.
    1. Shenna DH. Comparison of a conventional and an initial 2-month intensive drug regimen for treating pulmonary tuberculosis in Swaziland. Tuberc. 1984;65:101–104.
    1. Perriens JH, St. Louis M, Mukadi YB, Brown C, Prignot J, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. N Engl J Med. 1995;332:779–784.
    1. Tam CM, Chan SL, Lam CW, Leung CC, Kam KM, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Am J Respir Crit Care Med. 1998;157:1726–1733.
    1. Combs D, O'Brien R, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med. 1990;112:397–406.
    1. Pedral-Sampaio DB, Netto EM, Brites C, Bandeira AC, Guerra C, et al. Use of Rhu-GM-CFS in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis. 2003;7:245–252.
    1. Hong Kong Chest Service, Tuberculosis Research Centre M, British Medical Research Council. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Am Rev Respir Dis. 1984;130:23–28.
    1. Snider DE, Jr., Long MW, Cross FS, Farer LS. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Am Rev Respir Dis. 1984;129:573–579.
    1. Long MW, Snider D, Jr., Farer LS. U.S. public health service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Resp Dis. 1979;119:879–894.
    1. Tripathy SP. Madras study of short-course chemotherapy in pulmonary tuberculosis. Bull Int Union Tuberc. 1979;54:28–30.
    1. Murray J, Sonnenberg P, Shearer S, Godfrey-Faussett P. Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection. S Afr Med J. 2000;90:381–386.
    1. East African British Medical Research Councils. Controlled clinical trial of five short-course (4 month) chemotherapy regimens in pulmonary tuberculosis. Am Rev Respir Dis. 1981;123:165–170.
    1. Agounitestane D, Chiheb M, Khaled S, Khaled NA, Boulahbal F, et al. Essai thérapeutique d'une combinaison de trois médicaments essentiels dans la chimiothérapie courte de la tuberculose. Rev Mal Resp. 1990;7:209–213.
    1. Mazouni L, Tazir M, Boulahbal F, Chaulet P. Enquête contrôlée comparant trois règimes de chiniothérapie quotidienne de six mois dans la tuberculose pulmonaire, en pratique de routine à Alger. Rev Mal Resp. 1985;2:209–214.
    1. East African and British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Lancet. 1978;2:334.
    1. El-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis. 1998;26:1148–1158.
    1. British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis. Lancet. 1976;ii:1102.
    1. Teo SK, Tan KK, Khoo TK. Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months. Ann Acad Med Singapore. 2002;31:175–181.
    1. Chaulet P, Boulahbal F. Essai clinique d'une combinaison en proportions fixes de trois medicaments dans le traitement de la tuberculose. Tuberc Lung Dis. 1995;76:407–412.
    1. Engbaek HC, Heckscher T, Hojgaard C, Larsen SO, Rasmussen KN, et al. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972–1974. Eur J Respir Dis. 1981;63:84–93.
    1. Sharifi-Mood B, Metanat M, Alavi-Naini R, Kouhpayeh HR, Salehi M, et al. The comparison of six-month and four-month regimens of chemotherapy in the treatment of smear positive pulmonary tuberculosis. J Med Sci. 2006;6:108–111.
    1. A Singapore-British Medical Research Council study. Controlled trial of 4-month and 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Ann Acad Med. 1978;5:242–243.
    1. Maureen M, McGregor M, Olliaro P, Wolmarans L, Mabuza B, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;154:1462–1467.
    1. Hong Kong Chest Service, Tuberculosis Research Centre M, British Medical Research Council. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Am Rev Respir Dis. 1981;124:138–142.
    1. Mohanty KC, Dhamgaye TM. Controlled of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest. 1993;104:1194–1198.
    1. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest. 1992;102:1815–1818.
    1. Mak A, Thomas A, Granado M, Zaleskis R, Mouzafarova N, et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med. 2008;178:306–312.
    1. World Health Organization. Treatment of tuberculosis: Guidelines. 4th Edition. Geneva: WHO. WHO/HTM/TB/2009.420; 2009.
    1. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360:528–534.
    1. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174:1153–1158.
    1. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41:83–91.
    1. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897.
    1. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338:b1147.
    1. Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, et al. Delay in diagnosis among hospitalized patients with active tuberculosis—predictors and outcomes. Am J Respir Crit Care Med. 2002;165:927–933.
    1. Humphries MJ, Byfield SP, Darbyshire JH, Davies PDO, Nunn AJ, et al. Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest. 1984;78:149.
    1. Allan WGL, Snell NJC, Hill LE, Fayers PM, Scadding JG, et al. A survey of deaths in Hong Kong attributed to tuberculosis. Tuberc. 1981;62:1–11.
    1. Davis MCE, McAllister K, Matthews CJ, Ognibene AJ. Tuberculosis; cause of death in antibiotic era. Chest. 1985;88:726.
    1. Ramos JM, Padilla S, Masia M, Gutierrez F. A bibliometric analysis of tuberculosis research indexed in PubMed, 1997–2006. In J Tuberc Lung Dis. 2008;12:1461–1467.
    1. Kieling C, Herrman H, Patel V, Mari JJ. Indexation of psychiatric journals from low- and middle-income countries: a survey and a case study. World Psychiatry. 2009;8:40–44.
    1. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358:1687–1693.
    1. Hong Kong Chest Service, Tuberculosis Research Centre M-BMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145:36–41.
    1. East and Central African-British Medical Research Council Fifth Collaborative. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tuberc. 1986;67:5–15.
    1. Felten MK. Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis. S Afr Med J. 1989;75:524–526.
    1. East and Central African-British Medical Research Council Fifth Collaborative. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tuberc. 1986;67:5–15.
    1. East and Central African-British Medical Research Council Fifth Collaborative. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tuberc. 1986;67:5–15.
    1. Zierski M, Bek E, Long MW, Snider DE,, Jr. Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis. 1981;124:249–251.
    1. Zierski M, Bek E, Long MW, Snider DE,, Jr. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1980;122:879–889.
    1. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. S Afr Med J. 1994;84:325–327.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren